189 results on '"Havla J"'
Search Results
2. Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
- Author
-
Havla J, Kleiter I, and Kümpfel T
- Subjects
Therapeutics. Pharmacology ,RM1-950 - Abstract
Joachim Havla,1 Ingo Kleiter,2 Tania Kümpfel11Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig Maximilians University, Munich, 2Department of Neurology, St Josef Hospital, Ruhr University, Bochum, GermanyAbstract: Natalizumab (NAT) was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). While pivotal and post-marketing studies have showed considerable and sustained efficacy of NAT in RRMS, the increasing incidence of therapy-associated progressive multifocal leukoencephalopathy (PML), a brain infection caused by the John Cunningham virus (JCV), is a risk associated with long-term therapy. The risk for therapy-associated PML is highest in so-called “triple risk” patients. Therefore, long-term NAT-treated, immunosuppressive-pretreated, and JCV antibody-positive patients often discontinue NAT therapy. However, until now, it is not known which treatment strategy should be followed after NAT cessation. Since disease activity returns to pretreatment levels, or even above, within 4–7 months from the last infusion of NAT, patients who stop NAT are at considerable risk of relapse and worsening of multiple sclerosis (MS)-related disability. Several strategies have been applied to prevent the recurrence of disease activity after discontinuation of NAT. Of these, bridging with intravenous methylprednisolone, and switching to glatiramer acetate or interferon beta (IFN-beta) do not seem to be effective enough. More promising results have been obtained in retrospective studies and case series with fingolimod (FTY), an alternative escalation therapy for RRMS, although some patients have showed a severe disease rebound after starting FTY treatment. The time interval between the discontinuation of NAT and the start of FTY might affect the recurrence of disease activity. Long-term data about the efficacy and safety of FTY treatment after cessation of NAT are urgently needed and should be further investigated. Prospective studies are warranted, to optimize treatment strategies for RRMS patients who discontinue NAT, especially because new therapies will be available in the very near future.Keywords: natalizumab discontinuation, switching, bridging, drug holidays, multiple sclerosis
- Published
- 2013
3. Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode
- Author
-
Pakeerathan, T., Havla, J., Schwake, C., Salmen, A., Bigi, S., Abegg, M., Brügger, D., Ferrazzini, T., Runge, A.-K., Breu, M., Kornek, B., Bsteh, G., Felipe-Rucián, A., Ringelstein, M., Aktas, O., Karenfort, M., Wendel, E., Kleiter, I., Hellwig, K., Kümpfel, T., Thiels, C., Lücke, T., Gold, R., Rostasy, K., and Ayzenberg, I.
- Published
- 2022
- Full Text
- View/download PDF
4. Optical coherence tomography assessment of disease activity in cryopyrin‐associated periodic syndrome
- Author
-
Mulazzani, E., primary, Böhm, L., additional, Christmann, T., additional, Krumbholz, M., additional, Kümpfel, T., additional, and Havla, J., additional
- Published
- 2024
- Full Text
- View/download PDF
5. High socioeconomic impact on prescription behavior despite unrestricted access to disease-modifying therapies in people with multiple sclerosis.
- Author
-
Samadzadeh, S., Havla, J., Lepka, K., Brinks, R., Meuth, S. G., Klotz, L., and Albrecht, P.
- Subjects
DRUG bioavailability ,DRUG accessibility ,MEDICAL care ,DRUG prescribing ,GROSS domestic product - Abstract
Background: Economic and health care restraints strongly impact on drug prescription for chronic diseases. We aimed to identify potential factors for prescription behavior in chronic disease. Multiple sclerosis was chosen as a model disease due to its chronic character, incidence, and high socioeconomic impact. Methods: Germany was used as a model country as the health-care system is devoid of economic and drug availability restraints. German statutory health insurance data were analyzed retrospectively. The impact of number of university hospitals and neurologists as well as the gross domestic product (GDP) as potential factors on prescriptions of platform and high-efficacy disease-modifying therapies (DMTs) was analyzed. Results: Prescription of platform DMTs increased over time in almost all federal states with varying degree of increase. Univariate regression analysis showed that the prescription volume of platform DMTs positively correlated with the number of university hospitals and neurologists, as well as the GDP per federal state. Stepwise forward regression analysis including all potential factors indicated a statistically significant model for platform DMT (R² = 0.55; 95%-CI [0.28, 0.82]; p=0.001) revealing GDP as the main contributor. This was confirmed in the independent analysis. Conclusion: This study illustrates that even without overt drug prescription inequity, access to medication is not evenly distributed and depends on economic strength and regional medical care density. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Entzündliche Erkrankungen
- Author
-
Warnke, C., Havla, J., Kitzrow, M., Biesalski, A.-S., Knauss, S., Sturm, Dietrich, editor, Biesalski, Anne-Sophie, editor, and Höffken, Oliver, editor
- Published
- 2019
- Full Text
- View/download PDF
7. Seronegatives myasthenes Syndrom?
- Author
-
Selge, C., Kümpfel, T., Havla, J., Schöberl, F., Danek, A., and Reilich, P.
- Published
- 2020
- Full Text
- View/download PDF
8. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
- Author
-
Jarius, S., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Giglhuber, K., Häußler, V., Havla, J., Hellwig, K., Hümmert, M.W., Kleiter, I., Klotz, L., Krumbholz, M., Kümpfel, T., Paul, F., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J.P., Bergh, F.T., Tumani, H., Wildemann, B., and Trebst, C.
- Subjects
Function and Dysfunction of the Nervous System - Abstract
The term 'neuromyelitis optica spectrum disorders' (NMOSD) is used as an umbrella term that refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) and its formes frustes and to a number of closely related clinical syndromes without AQP4-IgG. NMOSD were originally considered subvariants of multiple sclerosis (MS) but are now widely recognized as disorders in their own right that are distinct from MS with regard to immunopathogenesis, clinical presentation, optimum treatment, and prognosis. In part 1 of this two-part article series, which ties in with our 2014 recommendations, the neuromyelitis optica study group (NEMOS) gives updated recommendations on the diagnosis and differential diagnosis of NMOSD. A key focus is on differentiating NMOSD from MS and from myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD), which shares significant similarity with NMOSD with regard to clinical and, partly, radiological presentation, but is a pathogenetically distinct disease. In part 2, we provide updated recommendations on the treatment of NMOSD, covering all newly approved drugs as well as established treatment options.
- Published
- 2023
9. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis
- Author
-
Unterrainer, Marcus, Mahler, C., Vomacka, L., Lindner, S., Havla, J., Brendel, M., Böning, G., Ertl-Wagner, B., Kümpfel, T., Milenkovic, V. M., Rupprecht, R., Kerschensteiner, M., Bartenstein, P., and Albert, Nathalie L.
- Published
- 2018
- Full Text
- View/download PDF
10. Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?
- Author
-
Gernert, J.A., primary, Zimmermann, H., additional, Oswald, E., additional, Christmann, T., additional, Kümpfel, T., additional, and Havla, J., additional
- Published
- 2022
- Full Text
- View/download PDF
11. Longitudinal retinal changes in MOGAD
- Author
-
Oertel, F.C., Sotirchos, E.S., Zimmermann, H.G., Motamedi, S., Specovius, S., Asseyer, E.S., Chien, C., Cook, L., Vasileiou, E., Filippatou, A., Calabresi, P.A., Saidha, S., Pandit, L., D'Cunha, A., Outteryck, O., Zéphir, H., Pittock, S., Flanagan, E.P., Bhatti, M.T., Rommer, P.S., Bsteh, G., Zrzavy, T., Kuempfel, T., Aktas, O., Ringelstein, M., Albrecht, P., Ayzenberg, I., Pakeerathan, T., Knier, B., Aly, L., Asgari, N., Soelberg, K., Marignier, R., Tilikete, C.F., Calvo, A.C., Villoslada, P., Sanchez-Dalmau, B., Martinez-Lapiscina, E.H., Llufriu, S., Green, A.J., Yeaman, M.R., Smith, T.J., Brandt, A.U., Chen, J., Paul, F., and Havla, J.
- Subjects
Function and Dysfunction of the Nervous System - Abstract
OBJECTIVE: Patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro-axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON-independent retinal atrophy can be detected in MOGAD. METHODS: Eighty MOGAD patients and 139 healthy controls (HC) were included. OCT data was acquired with 1) Spectralis spectral domain OCT (MOGAD (N=66) and HC (N=103)) and 2) Cirrus HD-OCT (MOGAD (N=14) and HC (N=36)). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fibre layer (pRNFL) were quantified. RESULTS: At baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD-ON) compared with MOGAD eyes without a history of ON (MOGAD-NON) and HC (p12 months ago (p
- Published
- 2022
12. Artificial intelligence extension of the OSCAR-IB criteria
- Author
-
Petzold, A., Albrecht, P., Balcer, L., Bekkers, E., Brandt, A. U., Calabresi, P. A., Deborah, O. G., Graves, J. S., Green, A., Keane, P. A., Nij Bijvank, J. A., Sander, J. W., Paul, F., Saidha, S., Villoslada, P., Wagner, S. K., Yeh, E. A., Aktas, O., Antel, J., Asgari, N., Audo, I., Avasarala, J., Avril, D., Bagnato, F. R., Banwell, B., Bar-Or, A., Behbehani, R., Manterola, A. B., Bennett, J., Benson, L., Bernard, J., Bremond-Gignac, D., Britze, J., Burton, J., Calkwood, J., Carroll, W., Chandratheva, A., Cohen, J., Comi, G., Cordano, C., Costa, S., Costello, F., Courtney, A., Cruz-Herranz, A., Cutter, G., Crabb, D., Delott, L., De Seze, J., Diem, R., Dollfuss, H., El Ayoubi, N. K., Fasser, C., Finke, C., Fischer, D., Fitzgerald, K., Fonseca, P., Frederiksen, J. L., Frohman, E., Frohman, T., Fujihara, K., Cuellar, I. G., Galetta, S., Garcia-Martin, E., Giovannoni, G., Glebauskiene, B., Suarez, I. G., Jensen, G. P., Hamann, S., Hartung, H. -P., Havla, J., Hemmer, B., Huang, S. -C., Imitola, J., Jasinskas, V., Jiang, H., Kafieh, R., Kappos, L., Kardon, R., Keegan, D., Kildebeck, E., Kim, U. S., Klistorner, S., Knier, B., Kolbe, S., Korn, T., Krupp, L., Lagreze, W., Leocani, L., Levin, N., Liskova, P., Preiningerova, J. L., Lorenz, B., May, E., Miller, D., Mikolajczak, J., Said, S. M., Montalban, X., Morrow, M., Mowry, E., Murta, J., Navas, C., Nolan, R., Nowomiejska, K., Oertel, F. C., Oh, J., Oreja-Guevara, C., Orssaud, C., Osborne, B., Outteryck, O., Paiva, C., Palace, J., Papadopoulou, A., Patsopoulos, N., Pontikos, N., Preising, M., Prince, J., Reich, D., Rejdak, R., Ringelstein, M., Rodriguez de Antonio, L., Sahel, J. -A., Sanchez-Dalmau, B., Sastre-Garriga, J., Schippling, S., Schuman, J., Shindler, K., Shin, R., Shuey, N., Soelberg, K., Specovius, S., Suppiej, A., Thompson, A., Toosy, A., Torres, R., Touitou, V., Trauzettel-Klosinski, S., van der Walt, A., Vermersch, P., Vidal-Jordana, A., Waldman, A. T., Waters, C., Wheeler, R., White, O., Wilhelm, H., Winges, K. M., Wiegerinck, N., Wiehe, L., Wisnewski, T., Wong, S., Wurfel, J., Yaghi, S., You, Y., Yu, Z., Yu-Wai-Man, P., Zemaitien≐, R., Zimmermann, H., Albrecht P., Petzold A., Balcer, L., Bekkers, E., Brandt, A. U., Calabresi, P. A., Deborah, O. G., Graves, J. S., Green, A., Keane, P. A., Nij Bijvank, J. A., Sander, J. W., Paul, F., Saidha, S., Villoslada, P., Wagner, S. K., Yeh, E. A., Aktas, O., Antel, J., Asgari, N., Audo, I., Avasarala, J., Avril, D., Bagnato, F. R., Banwell, B., Bar-Or, A., Behbehani, R., Manterola, A. B., Bennett, J., Benson, L., Bernard, J., Bremond-Gignac, D., Britze, J., Burton, J., Calkwood, J., Carroll, W., Chandratheva, A., Cohen, J., Comi, G., Cordano, C., Costa, S., Costello, F., Courtney, A., Cruz-Herranz, A., Cutter, G., Crabb, D., Delott, L., De Seze, J., Diem, R., Dollfuss, H., El Ayoubi, N. K., Fasser, C., Finke, C., Fischer, D., Fitzgerald, K., Fonseca, P., Frederiksen, J. L., Frohman, E., Frohman, T., Fujihara, K., Cuellar, I. G., Galetta, S., Garcia-Martin, E., Giovannoni, G., Glebauskiene, B., Suarez, I. G., P. , Jensen, G., Hamann, S., Hartung, H. -P., Havla, J., Hemmer, B., Huang, S. -C., Imitola, J., Jasinskas, V., Jiang, H., Kafieh, R., Kappos, L., Kardon, R., Keegan, D., Kildebeck, E., Kim, U. S., Klistorner, S., Knier, B., Kolbe, S., Korn, T., Krupp, L., Lagreze, W., Leocani, L., Levin, N., Liskova, P., Preiningerova, J. L., Lorenz, B., May, E., Miller, D., Mikolajczak, J., Said, S. M., Montalban, X., Morrow, M., Mowry, E., Murta, J., Navas, C., Nolan, R., Nowomiejska, K., Oertel, F. C., Oh, J., Oreja-Guevara, C., Orssaud, C., Osborne, B., Outteryck, O., Paiva, C., Palace, J., Papadopoulou, A., Patsopoulos, N., Pontikos, N., Preising, M., Prince, J., Reich, D., Rejdak, R., Ringelstein, M., Rodriguez de Antonio, L., Sahel, J. -A., Sanchez-Dalmau, B., Sastre-Garriga, J., Schippling, S., Schuman, J., Shindler, K., Shin, R., Shuey, N., Soelberg, K., Specovius, S., Suppiej, A., Thompson, A., Toosy, A., Torres, R., Touitou, V., Trauzettel-Klosinski, S., van der Walt, A., Vermersch, P., Vidal-Jordana, A., Waldman, A. T., Waters, C., Wheeler, R., White, O., Wilhelm, H., Winges, K. M., Wiegerinck, N., Wiehe, L., Wisnewski, T., Wong, S., Wurfel, J., Yaghi, S., You, Y., Yu, Z., Yu-Wai-Man, P., Zemaitien≐, R., and Zimmermann, H.
- Subjects
0301 basic medicine ,Big Data ,medicine.medical_specialty ,Neurology ,media_common.quotation_subject ,Big data ,MEDLINE ,Reviews ,Socio-culturale ,Neurosciences. Biological psychiatry. Neuropsychiatry ,Review ,Public domain ,Retina ,Cohort Studies ,03 medical and health sciences ,Annotation ,0302 clinical medicine ,Artificial Intelligence ,medicine ,Humans ,Quality (business) ,RC346-429 ,Tomography ,media_common ,Image pattern recognition ,business.industry ,General Neuroscience ,Nervous System Diseases ,Tomography, Optical Coherence ,Algorithms ,030104 developmental biology ,Optical Coherence ,Imaging technology ,RC0321 ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Artificial intelligence ,sense organs ,business ,030217 neurology & neurosurgery ,RC321-571 - Abstract
Artificial intelligence (AI)‐based diagnostic algorithms have achieved ambitious aims through automated image pattern recognition. For neurological disorders, this includes neurodegeneration and inflammation. Scalable imaging technology for big data in neurology is optical coherence tomography (OCT). We highlight that OCT changes observed in the retina, as a window to the brain, are small, requiring rigorous quality control pipelines. There are existing tools for this purpose. Firstly, there are human‐led validated consensus quality control criteria (OSCAR‐IB) for OCT. Secondly, these criteria are embedded into OCT reporting guidelines (APOSTEL). The use of the described annotation of failed OCT scans advances machine learning. This is illustrated through the present review of the advantages and disadvantages of AI‐based applications to OCT data. The neurological conditions reviewed here for the use of big data include Alzheimer disease, stroke, multiple sclerosis (MS), Parkinson disease, and epilepsy. It is noted that while big data is relevant for AI, ownership is complex. For this reason, we also reached out to involve representatives from patient organizations and the public domain in addition to clinical and research centers. The evidence reviewed can be grouped in a five‐point expansion of the OSCAR‐IB criteria to embrace AI (OSCAR‐AI). The review concludes by specific recommendations on how this can be achieved practically and in compliance with existing guidelines.
- Published
- 2021
13. Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody-associated disease: CHANCE(NMO) study
- Author
-
Hümmert, M.W., Schöppe, L.M., Bellmann-Strobl, J., Siebert, N., Paul, F., Duchow, A., Pellkofer, H., Kümpfel, T., Havla, J., Jarius, S., Wildemann, B., Berthele, A., Bergh, F.T., Pawlitzki, M., Klotz, L., Kleiter, I., Stangel, M., Gingele, S., Weber, M.S., Faiss, J.H., Pul, R., Walter, A., Zettl, U., Senel, M., Stellmann, J.P., Häußler, V., Hellwig, K., Ayzenberg, I., Aktas, O., Ringelstein, M., Schreiber-Katz, O., and Trebst, C.
- Subjects
Function and Dysfunction of the Nervous System ,health care economics and organizations - Abstract
OBJECTIVE: To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-antibody associated disease (MOGAD).MethodsIn this multicenter cross-sectional study, data on consumption of medical and non-medical resources and work ability were assessed via patient questionnaires. Costs were analyzed in EUR for 2018 from the societal perspective. HRQoL was captured by the EuroQoL EQ-5D-5L questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. RESULTS: Two hundred twelve patients (80% women; median age 50 [19-83] years; median disease duration 7 [0-43] years; median Expanded Disability Status Scale [EDSS] 3.5 [0-8.5]; 66% Aquaporin-4 IgG, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for EUR (Euro) 59 574 (95% CI 51 225 to 68 293; USD [United States dollars] 70 297, 95% CI 60 445 to 80 586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65 to 0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%) and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ=0.56, 95% CI 0.45 to 0.65); in the EDSS 6.5-8.5 subgroup the mean annual costs were EUR 129 687 (95% CI 101 946 to 160 336; USD 153 031, 95% CI 120 296 to 189 196). The HRQoL revealed a negative correlation to disease severity (ρ=-0.69, 95% CI -0.76 to -0.61); in the EDSS 6.5-8.5 subgroup the EQ-5D-5L mean index value was 0.195 (95% CI 0.13 to 0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. CONCLUSION: These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and preserve quality of life.
- Published
- 2022
14. Immuntherapie der multiplen Sklerose: Überblick und Update
- Author
-
Havla, J., Kümpfel, T., and Hohlfeld, R.
- Published
- 2015
- Full Text
- View/download PDF
15. Absence of astrocytic outer retinal layer thinning in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
- Author
-
Lu, A., Zimmermann, H. G., Specovius, S., Motamedi, S., Chien, C., Lana-Peixoto, M. Aurelio, Fontenelle, M. Andrade, Ashtari, F., Kafieh, R., Pandit, L., Dcunha, A., Kim, H., Hyun, J. -W., Leocani, L., Pisa, M., Radaelli, M., Siritho, S., May, E. F., Tongco, C., de Seze, J., Senger, T., Palace, J., Roca-Fernandez, A., Stiebel-Kalish, H., Asgari, N., Soelberg, K. K., Martinez-Lapiscina, E. H., Havla, J., Mao-Draayer, Y., Rimler, Z., Reid, A., Marignier, R., Calvo, A., Altintas, A., Tanriverdi, U., Ringelstein, M., Albrecht, P., Tavares, I. M., Bichuetti, D., Jacob, A., Huda, S., de Castillo, I. S., Petzold, A., Green, A. J., Yeaman, M. R., Smith, T. J., Cook, L., Paul, F., Brandt, A. U., Oertel, F. C., and Consortiu, GJCF Int Clinical
- Published
- 2021
16. Longitudinal retinal optical coherence tomography in myelin oligodendrocyte glycoprotein antibody disorders
- Author
-
Oertel, F. C., Sotirchos, E. S., Zimmermann, H. G., Specovius, S., Chien, C., Motamedi, S., Cook, L., Vasileiou, E., Filippatou, A., Calabresi, P. A., Saidha, S., Pandit, L., D'Cunha, A., Outteryck, O., Pittock, S., Flanagan, E. P., Rommer, P. S., Bsteh, G., Aktas, O., Ringelstein, M., Albrecht, P., Ayzenberg, I., Knier, B., Aly, L., Asgari, N., Soelberg, K., Marignier, R., Tilikete, C. F., Calvo, A. Cobo, Martinez-Lapiscina, E. H., Green, A. J., Yeaman, M. R., Smith, T. J., Brandt, A. U., Chen, J., Paul, F., and Havla, J.
- Published
- 2021
17. PAMRINO: International MRI and clinical data repository for neuromyelitis optica spectrum disorder cohort description
- Author
-
Chien, C., Silva, V. Cruz, Geiter, E., Zimmermann, H., Specovius, S., Oertel, F. C., Bichuetti, D. B., Idagawa, M., Altintas, A., Tanriverdi, U., Siritho, S., Pandit, L., Dcunha, A., Sa, M. J., Figueiredo, R., Tongco, C., Qian, P., Lotan, I., Khasminsky, V., Hellmann, M., Stiebel-Kalish, H., Rotstein, D., Waxman, L., Ontaneda, D., Nakamura, K., Abboud, H., Subei, M. O., Mao-Draayer, Y., Havla, J., Asgari, N., Skejo, P., Kister, I., Rimler, Z., Reid, A., Ringelstein, M., Broadley, S., Arnett, S., Marron, B., Jolley, A., Wunderlich, M., Green, S., Cook, L., Yeaman, M. R., Smith, T. J., Brandt, A. U., Wuerfel, J., Paul, F., and NMOSD, GICC
- Published
- 2021
18. Pain, depression and quality of life in adults with MOG-antibody associated disease
- Author
-
Asseyer, S., Henke, E., Trebst, C., Hümmert, M.W., Wildemann, B., Jarius, S., Ringelstein, M., Aktas, O., Pawlitzki, M., Korsen, M., Klotz, L., Siebert, N., Ruprecht, K., Bellmann-Strobl, J., Wernecke, K.D., Häußler, V., Havla, J., Gahlen, A., Gold, R., Paul, F., Kleiter, I., and Ayzenberg, I.
- Subjects
Function and Dysfunction of the Nervous System - Abstract
BACKGROUND AND PURPOSE: Myelin oligodendrocyte glycoprotein-antibody (MOG-ab)-associated disease (MOGAD) is an inflammatory autoimmune condition of the CNS. However, data on pain and depression have remained scarce. The aim of this study was to assess features of chronic pain and depression as well as their impact on health-related quality of life (hr-QoL) in MOGAD. METHODS: Patients with MOGAD were identified in the Neuromyelitis Optica Study Group (NEMOS) registry. Data were acquired by a questionnaire, including clinical, demographic, pain (PainDetect, Brief Pain Inventory - short form, McGill Pain Questionnaire - short form), depression (Beck Depression Inventory-II), and hr-QoL (Short Form-36 Health Survey) items. RESULTS: Twenty-two of 43 patients suffered from MOGAD-related pain (11 nociceptive, 8 definite neuropathic, 3 possible neuropathic) and 18 from depression. Patients with neuropathic pain had highest pain intensity and most profound ADL impairment. Fifteen patients reported spasticity-associated pain, including four with short-lasting painful tonic spasms. Later disease onset, profound physical impairment and depression were associated with chronic pain. Physical QoL was more affected in pain-sufferers (p
- Published
- 2021
19. Optical coherence tomography in aquaporin-4-IgG positive neuromyelitis optica spectrum disorders: a collaborative multi-center study
- Author
-
Oertel, F. C., Specovius, S., Zimmermann, H., Chien, C., Motamedi, S., Cook, L., Lana-Peixoto, M. A., Fontenelle, M., Kim, H. J., Hyun, J. -W, Palace, J., Roca-Fernandez, A., Ashtari, F., Kafieh, R., Pandit, L., D Cunha, A., Aktas, O., Ringelstein, M., May, E., Tongco, C., Leocani, L., Pisa, M., Radaelli, M., Martinez-Lapiscina, E., Stiebel-Kalish, H., Siritho, S., Seze, J., Senger, T., Havla, J., Marignier, R., Nerrant, E., Calvo, A. Cobo, Bichuetti, D., Ivan Tavares, Asgari, N., Soelberg, K. K., Altintas, A., Tanriverdi, U., Jacob, A., Huda, S., Rimler, Z., Mao-Draayer, Y., Castillo, I. Soto, Green, A., Yeaman, M., Smith, T., Brandt, A., and Paul, F.
- Published
- 2020
20. Reproduzierbarkeit und Reliabilität des Phonovibrogramms: Quantifizierung gesunder Stimmlippenschwingungen
- Author
-
Havla, J., Döllinger, M., Eysholdt, U., and Lohscheller, J.
- Published
- 2009
- Full Text
- View/download PDF
21. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders
- Author
-
Motamedi, S., Oertel, F.C., Yadav, S.K., Kadas, E.M., Weise, M., Havla, J., Ringelstein, M., Aktas, O., Albrecht, P., Ruprecht, K., Bellmann-Strobl, J., Zimmermann, H.G., Paul, F., and Brandt, A.U.
- Subjects
genetic structures ,sense organs ,Function and Dysfunction of the Nervous System ,eye diseases - Abstract
OBJECTIVE: To investigate disease-specific foveal shape changes in patients with neuromyelitis optica spectrum disorders (NMOSDs) using foveal morphometry. METHODS: This cross-sectional study included macular spectral domain optical coherence tomography scans of 52 eyes from 28 patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD, 116 eyes from 60 patients with MS, and 123 eyes from 62 healthy controls (HCs), retrospectively, and an independent confirmatory cohort comprised 33/33 patients with NMOSD/MS. The fovea was characterized using 3D foveal morphometry. We included peripapillary retinal nerve fiber layer (pRNFL) thickness and combined macular ganglion cell and inner plexiform layer (GCIPL) volume to account for optic neuritis (ON)-related neuroaxonal damage. RESULTS: Group comparison showed significant differences compared with HC in the majority of foveal shape parameters in NMOSD, but not MS. Pit flat disk area, average pit flat disk diameter, inner rim volume, and major slope disk length, as selected parameters, showed differences between NMOSD and MS (p value = 0.017, 0.002, 0.005, and 0.033, respectively). This effect was independent of ON. Area under the curve was between 0.7 and 0.8 (receiver operating characteristic curve) for discriminating between NMOSD and MS. Pit flat disk area and average pit flat disk diameter changes independent of ON were confirmed in an independent cohort. CONCLUSIONS: Foveal morphometry reveals a wider and flatter fovea in NMOSD in comparison to MS and HC. Comparison to MS and accounting for ON suggest this effect to be at least in part independent of ON. This supports a primary retinopathy in AQP4-IgG–seropositive NMOSD.
- Published
- 2020
22. BMJ Open
- Author
-
Specovius, S. (Svenja), Zimmermann, H. (Hanna) G. (G), Oertel, F. (Frederike) C. (Cosima), Chien, C. (Claudia), Bereuter, C. (Charlotte), Cook, L. (Lawrence) J. (J), Lana Peixoto, M. (Marco) A. (Aurélio), Fontenelle, M. (Mariana) A. (Andrade), Kim, H. (Ho) J. (Jin), Hyun, J. (Jae-Won), Jung, S. (Su-Kyung), Palace, J. (Jacqueline), Roca-Fernandez, A. (Adriana), Diaz, A. (Alejandro) R. (Rubio), Leite, M. (Maria) I. (Isabel), Sharma, S. (Srilakshmi) M. (M), Ashtari, F. (Fereshte), Kafieh, R. (Rahele), Dehghani, A. (Alireza), Pourazizi, M. (Mohsen), Pandit, L. (Lekha), Dcunha, A. (Anitha), Aktas, O. (Orhan), Ringelstein, M. (Marius), Albrecht, P. (Philipp), May, E. (Eugene), Tongco, C. (Caryl), Leocani, L. (Letizia), Pisa, M. (Marco), Radaelli, M. (Marta), Martinez-Lapiscina, E. (Elena) H. (H), Stiebel-Kalish, H. (Hadas), Hellmann, M. (Mark), Lotan, I. (Itay), Siritho, S. (Sasitorn), De Sèze, J. (Jérôme), Senger, T. (Thomas), Havla, J. (Joachim), Marignier, R. (Romain), Tilikete, C. (Caroline), Cobo Calvo, A. (Alvaro), Bichuetti, D. (Denis) B. (Bernardi), Tavares, I. (Ivan) M. (Maynart), Asgari, N. (Nasrin), Soelberg, K. (Kerstin), Altintas, A. (Ayse), Yildirim, R. (Rengin), Tanriverdi, U. (Uygur), Jacob, A. (Anu), Huda, S. (Saif), Rimler, Z. (Zoe), Reid, A. (Allyson), Mao-Draayer, Y. (Yang), de Castillo, I. (Ibis) S. (Soto), Yeaman, M. (Michael) R. (R), Smith, T. (Terry) J. (J), Brandt, A. (Alexander) U. (U), and Paul, F. (Friedemann)
- Subjects
Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] - Abstract
PURPOSE: Optical coherence tomography (OCT) captures retinal damage in neuromyelitis optica spectrum disorders (NMOSD). Previous studies investigating OCT in NMOSD have been limited by the rareness and heterogeneity of the disease. The goal of this study was to establish an image repository platform, which will facilitate neuroimaging studies in NMOSD. Here we summarise the profile of the Collaborative OCT in NMOSD repository as the initial effort in establishing this platform. This repository should prove invaluable for studies using OCT to investigate NMOSD. PARTICIPANTS: The current cohort includes data from 539 patients with NMOSD and 114 healthy controls. These were collected at 22 participating centres from North and South America, Asia and Europe. The dataset consists of demographic details, diagnosis, antibody status, clinical disability, visual function, history of optic neuritis and other NMOSD defining attacks, and OCT source data from three different OCT devices. FINDINGS TO DATE: The cohort informs similar demographic and clinical characteristics as those of previously published NMOSD cohorts. The image repository platform and centre network continue to be available for future prospective neuroimaging studies in NMOSD. For the conduct of the study, we have refined OCT image quality criteria and developed a cross-device intraretinal segmentation pipeline. FUTURE PLANS: We are pursuing several scientific projects based on the repository, such as analysing retinal layer thickness measurements, in this cohort in an attempt to identify differences between distinct disease phenotypes, demographics and ethnicities. The dataset will be available for further projects to interested, qualified parties, such as those using specialised image analysis or artificial intelligence applications.
- Published
- 2020
23. Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis
- Author
-
Aly, L., primary, Havla, J., additional, Lepennetier, G., additional, Andlauer, T. F. M., additional, Sie, C., additional, Strauß, E.‐M., additional, Hoshi, M.‐M., additional, Kümpfel, T., additional, Hiltensperger, M., additional, Mitsdoerffer, M., additional, Mühlau, M., additional, Zimmer, C., additional, Hemmer, B., additional, Korn, T., additional, and Knier, B., additional
- Published
- 2020
- Full Text
- View/download PDF
24. An international retrospective multi-center study of retinal optical coherence tomography in neuromyelitis optica spectrum disorders: the CROCTINO study
- Author
-
Oertel, F. C., Specovius, S., Zimmermann, H. G., Chien, C., Motamedi, S., Cook, L., Martinez-Lapiscina, E. H., Lana Peixoto, M. A., Fontenelle, M. A., Palace, J., Roca-Fernandez, A., Siritho, S., Altintas, A., Tanriverdi, U., Jacob, A., Huda, S., Marignier, R., Nerrant, E., Calvo, A. Cobo, de Seze, J., Senger, T., Pandit, L., Dcunha, A., de Castillo, I. S., Bichuetti, D., Tavares, M., May, E. F., Tongco, C., Havla, J., Leocani, L., Pisa, M., Ashtari, F., Kafieh, R., Aktas, O., Ringelstein, M., Albrecht, P., Kim, H. J., Hyun, J. -W., Asgari, N., Soelberg, K., Mao-Draayer, Y., Stiebel-Kalish, H., Rimler, Z., Reid, A., Yeaman, M., Smith, T. J., Brandt, A. U., Paul, F., and NMOSD, GJCF Int Clinical Consortium
- Published
- 2019
25. The CROCTINO project: an international retrospective multi-center study of retinal optical coherence tomography in 501 patients with neuromyelitis optica spectrum disorders
- Author
-
Specovius, S., Zimmermann, H. G., Chien, C., Oertel, F. C., Cooke, L., Martinez-Lapiscina, E. H., Lana-Peixoto, M. A., Fontenelle, M. A., Palaces, J., Roca-Fernandez, A., Diaz, A. Rubio, Leiter, M. I., Sharma, S. M., Siritho, S., Altintas, A., Yildirim, R., Tanriverdi, U., Jacob, A., Huda, S., Marignier, R., Nerrant, E., Cobo-Calvo, A., de Seze, J., Senger, T., Pandit, L., Dcunha, A., Soto de Castillo, I., Bichuetti, D., Maynart Tavares, I., May, E. F., Tongco, C., Havla, J., Leocani, L., Pisa, M., Radaelli, M., Aktas, O., Ringelstein, M., Rybak, J., Albrecht, P., Kim, H. J., Hyun, J. -W., Asgari, N., Soelberg, K., Mao-Draayer, Y., Stiebel-Kalish, H., Kister, I., Rimler, Z., Reid, A., Brandt, A. U., Paul, F., and [Unknown], GJCF-ICC
- Published
- 2018
26. Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions
- Author
-
Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K.D., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., Kümpfel, T., Aktas, O., Hartung, H.P., Ringelstein, M., Geis, C., Kleinschnitz, C., Berthele, A., Hemmer, B., Angstwurm, K., Stellmann, J.P., Schuster, S., Stangel, M., Lauda, F., Tumani, H., Mayer, C., Krumbholz, M., Zeltner, L., Ziemann, U., Linker, R., Schwab, M., Marziniak, M., Then Bergh, F., Hofstadt-van Oy, U., Neuhaus, O., Zettl, U.K., Faiss, J., Wildemann, B., Paul, F., Jarius, S., Trebst, C., and NEMOS (Neuromyelitis Optica Study Group)
- Subjects
ddc:610 ,Function and Dysfunction of the Nervous System - Abstract
Objective: To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR). Methods: This retrospective cohort study was based on the registry of the German Neuromyelitis Optica Study Group, a nationwide network established in 2008. It recruited patients with neuromyelitis optica diagnosed according to the 2006 Wingerchuk criteria or with aquaporin-4 (AQP4-ab)-antibody–seropositive NMOSD treated at 6 regional hospitals and 16 tertiary referral centers until March 2013. Besides descriptive data analysis of patient and attack characteristics, generalized estimation equation (GEE) analyses were applied to compare the effectiveness of the 2 apheresis techniques. A GEE model was generated to assess predictors of outcome. Results: Two hundred and seven attacks in 105 patients (87% AQP4-ab-antibody seropositive) were treated with at least 1 apheresis therapy. Neither PE nor IA was proven superior in the therapy of NMOSD attacks. CR was only achieved with early apheresis therapy. Strong predictors for CR were the use of apheresis therapy as first-line therapy (OR 12.27, 95% CI: 1.04–144.91, p = 0.047), time from onset of attack to start of therapy in days (OR 0.94, 95% CI: 0.89–0.99, p = 0.014), the presence of AQP4-ab-antibodies (OR 33.34, 95% CI: 1.76–631.17, p = 0.019), and monofocal attack manifestation (OR 4.71, 95% CI: 1.03–21.62, p = 0.046). Conclusions: Our findings suggest early use of an apheresis therapy in NMOSD attacks, particularly in AQP4-ab-seropositive patients. No superiority was shown for one of the 2 apheresis techniques. Classification of evidence: This study provides Class IV evidence that for patients with NMOSD, neither PE nor IA is superior in the treatment of attacks.
- Published
- 2018
27. Seronegatives myasthenes Syndrom?
- Author
-
Selge, C., primary, Kümpfel, T., additional, Havla, J., additional, Schöberl, F., additional, Danek, A., additional, and Reilich, P., additional
- Published
- 2019
- Full Text
- View/download PDF
28. Mögliche Prädiktoren für das Auftreten systemischer NW unter Therapie mit IFN β bei Patienten mit MS
- Author
-
Kümpfel, T., Gerdes, L.A., Havla, J., Lohse, P., and Hohlfeld, R.
- Published
- 2010
- Full Text
- View/download PDF
29. P422: Tau-PET imaging with THK-5351 in patients with clinicallydiagnosed progressive supranuclear palsy
- Author
-
Brendel, M., Havla, J., Höglinger, Günter, Botzel, K., Danek, A., Rominger, A., and Levin, Johannes
- Subjects
ddc:610 - Abstract
Intracellular inclusions composed of the abnormally-modifiedmicrotubule-binding protein tau, are the second most common causeof frontotemporal lobar degeneration neuropathology (i.e. FTLD-tau). FTLD-tau pathology can manifest clinically with several formsof frontotemporal dementia (FTD) syndromes, like behavioural-variant FTD, progressive non-fluent aphasia, corticobasal syndromeand progressive supranuclear palsy (PSP). Especially in early stagesof the disease when many clinical phenotypes overlap there are atpresent no reliable means to identify the underlying neuropathologyin vivo. However, as effective disease-modifying treatments shouldbe administered before irreversible neuronal damage has occurred,an early detection of the underlying neuropathological processbecomes increasingly important. THK-5351 is a novel Tau-PETligand that may allow in vivo visualization and quantification of taudeposits.THK-5351 PET was performed in 7 patients with probable PSPaccording to current criteria. PET scans were acquired 40–60 minpost injection and were co-registered to MRI. Visual and semi-quantitative analysis of tracer binding (standardized uptake valueratio) in predefined cortical areas was performed using the cerebellarcortex a reference.Increased THK-5351 binding was detectable in striatum, thala-mus and brainstem, especially in the midbrain. 6/7 subjects indicatedclearly elevated THK-5351 uptake in the midbrain (SUVR: 2.8 - 3.9) compared to non-suspect PSP (SUVR: 2.2). One subjectsuspect to PSP with innate hydrocephalus, did not show an elevatedTHK-5351 midbrain signal (SUVR: 2.1), suggesting no underlyingtauopathy in this case.THK-5351 binding patterns correlated well with the knowndistribution of tau-pathology at autopsy in PSP. THK-5351 seems tobe a useful in vivo biomarker of tau burden and may thereforefacilitate earlier and more reliable diagnosis of an underlyingtauopathy.
- Published
- 2016
30. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis.
- Author
-
Unterrainer, Marcus, Mahler, C., Vomacka, L., Lindner, S., Havla, J., Brendel, M., Böning, G., Ertl-Wagner, B., Kümpfel, T., Milenkovic, V. M., Rupprecht, R., Kerschensteiner, M., Bartenstein, P., and Albert, Nathalie L.
- Subjects
POSITRON emission tomography ,MAGNETIC resonance imaging ,MACROPHAGES ,TRANSLOCATOR proteins - Abstract
Purpose: Expression of the translocator protein (TSPO) is upregulated in activated macrophages/microglia and is considered to be a marker of neuroinflammation. We investigated the novel TSPO ligand [
18 F]GE-180 in patients with relapsing-remitting multiple sclerosis (RRMS) to determine the feasibility of [18 F]GE-180 PET imaging in RRMS patients and to assess its ability to detect active inflammatory lesions in comparison with the current gold standard, contrast-enhanced magnetic resonance imaging (MRI).Methods: Nineteen RRMS patients were prospectively included in this study. All patients underwent TSPO genotyping and were classified as high-affinity, medium-affinity or low-affinity binders (HAB/MAB/LAB). PET scans were performed after administration of 189 ± 12 MBq [18 F]GE-180, and 60-90 min summation images were used for visual analysis and assessment of standardized uptake values (SUV). The frontal nonaffected cortex served as a pseudoreference region (PRR) for evaluation of SUV ratios (SUVR). PET data were correlated with MRI signal abnormalities, i.e. T2 hyperintensity or contrast enhancement (CE). When available, previous MRI data were used to follow the temporal evolution of individual lesions.Results: Focal lesions were identified as hot spots by visual inspection. Such lesions were detected in 17 of the 19 patients and overall 89 [18 F]GE-180-positive lesions were found. TSPO genotyping revealed 11 patients with HAB status, 5 with MAB status and 3 with LAB status. There were no associations between underlying binding status (HAB, MAB and LAB) and the signal intensity in either lesions (SUVR 1.87 ± 0.43, 1.95 ± 0.48 and 1.86 ± 0.80, respectively; p = 0.280) or the PRR (SUV 0.36 ± 0.03, 0.40 ± 0.06 and 0.37 ± 0.03, respectively; p = 0.990). Of the 89 [18 F]GE-180-positive lesions, 70 showed CE on MRI, while the remainder presented as T2 lesions without CE. SUVR were significantly higher in lesions with CE than in those without (2.00 ± 0.53 vs. 1.60 ± 0.15; p = 0.001). Notably, of 19 [18 F]GE-180-positive lesions without CE, 8 previously showed CE, indicating that [18 F]GE-180 imaging may be able to detect lesional activity that is sustained beyond the blood-brain barrier breakdown.Conclusion: [18 F]GE-180 PET can detect areas of focal macrophage/microglia activation in patients with RRMS in lesions with and without CE on MRI. Therefore, [18 F]GE-180 PET imaging is a sensitive and quantitative approach to the detection of active MS lesions. It may provide information beyond contrast-enhanced MRI and is readily applicable to all patients. [18 F]GE-180 PET imaging is therefore a promising new tool for the assessment of focal inflammatory activity in MS. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
31. Neurological manifestations in autoinflammatory syndromes: a series of 131 patients from our neuroimmunology departement
- Author
-
Schuh, E, primary, Lohse, P, additional, Havla, J, additional, Meinl, I, additional, Gerdes, L-A, additional, Hohlfeld, R, additional, and Kümpfel, T, additional
- Published
- 2015
- Full Text
- View/download PDF
32. Immunotherapies for multiple sclerosis
- Author
-
Havla, J., primary, Kümpfel, T., additional, and Hohlfeld, R., additional
- Published
- 2015
- Full Text
- View/download PDF
33. Humane Chondrozyten und Lymphozyten als Modell zur Evaluation potentiell toxischer Effekte von Trägersubstanzen für das Tissue Engineering
- Author
-
Kleinsasser, N, Lotz, A, Havla, J, and Staudenmaier, R
- Subjects
ddc: 610 - Published
- 2008
34. Quantification of vocal fold dynamics based on phonovibrograms
- Author
-
Havla, J, Döllinger, M, Eysholdt, U, and Lohscheller, J
- Subjects
ddc: 610 - Abstract
Mit endoskopischen Hochgeschwindigkeitsaufnahmen (HG-Aufnahmen) lassen sich die Bewegungsmuster der Stimmlippen in Echtzeit erfassen. Für eine quantitative und damit objektive Analyse der HG-Aufnahmen wurde die Phonovibrographie entwickelt. Mit diesem Verfahren werden die oszillierenden Stimmlippenkanten aus den HG-Aufnahmen extrahiert und anschließend in einem 2D Bild, dem Phonovibrogramn (PVG), visualisiert. Durch Quantifizierung der geometrischen Muster innerhalb eines PVGs lassen sich die Schwingungen beider Stimmlippen unabhängig voneinander analysieren. In der hier vorgestellten Studie wurde die Phonovibrographie zur Analyse von 12 gesunden männlichen und 12 weiblichen Probanden verwendet. Um die Stabilität des Verfahrens zu verifizieren, wurden von jeder HG-Aufnahme eines Probanden zwei Teilsequenzen analysiert. Anschließend wurden die Schwingungsmuster für beide Teilsequenzen getrennt voneinander quantifiziert. Bei allen Probanden stimmen die Ergebnisse der PVG-Analyse beider Teilsequenzen in hohem Maße miteinander überein. Normale Stimmlippenschwingungen lassen sich somit mit dem PVG-Verfahren reproduzierbar quantifizieren. Dies stellt eine wichtige Voraussetzung für die klinische Verwendbarkeit des Verfahrens dar. Die PVG-Analyse zeigt sich weiterhin so sensitiv, dass Schwingungsmuster verschiedener Probanden eindeutig voneinander unterschieden werden können. In weiterführenden Studien soll die Anwendbarkeit der Phonovibrographie zur Differenzierung gesunder und pathologischer Stimmgebung untersucht werden.
- Published
- 2007
35. Phonovibrography - Kategorisierung von Stimmlippenschwingungen der Regensburger Domspatzen
- Author
-
Havla, J, Toy, H, Rosanowski, F, Döllinger, M, Eysholdt, U, and Lohscheller, J
- Subjects
ddc: 610 - Abstract
Endoskopische Hochgeschwindigkeitsaufnahmen (HG-Aufnahmen) eröffnen neue Möglichkeiten in der Bewertung und Klassifizierung von Stimmlippenschwingungen. In der klinischen Praxis wird die Bewertung von HG-Aufnahmen - ebenso wie die der Stroboskopie - nach der Empfehlung der European Laryngological Society (ELS) vorgenommen und ist vorwiegend subjektiver Natur. Eine objektive Beschreibung von Schwingungsvorgängen ist mittels der neu eingeführten Phonovibrography möglich. Durch Erzeugung so genannter Phonovibrogramme (PVG) lässt sich der komplexe Schwingungsvorgang von Stimmlippen in einer zweidimensionalen Darstellung visualisieren. Wir haben an einem Kollektiv von 31 Sängern der Regensburger Domspatzen 104 HG-Aufnahmen durchgeführt. Ziel der Untersuchung war die Fragestellung, inwieweit eine Klassifizierung ausgebildeter Sängerstimmen anhand der phonovibrographischen Darstellung möglich ist. Zudem wurde die Abhängigkeit der Schwingungsmuster vom verwendeten Untersuchungsparadigma untersucht. Dazu wurden HG-Aufnahmen während einer gehaltenen Phonation, einer Grundfrequenzerhöhung und -verminderung, sowie eines Crescendos durchgeführt. Die Auswertung der berechneten PVGs zeigt, dass sich aus der Gesamtheit aller HG-Aufnahmen eine Grundmenge von Schwingungstypen bestimmen lässt. Die an verschiedenen Stellen ausgewerteten HG-Aufnahmen ermöglichen die Detektion individueller Schwingungsmuster, welche sich den PVG-Kategorie zuordnen lassen.
- Published
- 2006
36. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
- Author
-
Schwab, N., primary, Schneider-Hohendorf, T., additional, Posevitz, V., additional, Breuer, J., additional, Gobel, K., additional, Windhagen, S., additional, Brochet, B., additional, Vermersch, P., additional, Lebrun-Frenay, C., additional, Posevitz-Fejfar, A., additional, Capra, R., additional, Imberti, L., additional, Straeten, V., additional, Haas, J., additional, Wildemann, B., additional, Havla, J., additional, Kumpfel, T., additional, Meinl, I., additional, Niessen, K., additional, Goelz, S., additional, Kleinschnitz, C., additional, Warnke, C., additional, Buck, D., additional, Gold, R., additional, Kieseier, B. C., additional, Meuth, S. G., additional, Foley, J., additional, Chan, A., additional, Brassat, D., additional, and Wiendl, H., additional
- Published
- 2013
- Full Text
- View/download PDF
37. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group”
- Author
-
Havla, J, primary, Berthele, A, additional, Kümpfel, T, additional, Krumbholz, M, additional, Jochim, A, additional, Kronsbein, H, additional, Ryschkewitsch, C, additional, Jensen, P, additional, Lippmann, K, additional, Hemmer, B, additional, Major, E, additional, and Hohlfeld, R, additional
- Published
- 2012
- Full Text
- View/download PDF
38. Aktuelle Diagnostik und Therapie der Multiplen Sklerose
- Author
-
Havla, J., additional, Kümpfel, T., additional, and Hohlfeld, R., additional
- Published
- 2012
- Full Text
- View/download PDF
39. Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis
- Author
-
Kümpfel, T, primary, Gerdes, L-A, additional, Wacker, T, additional, Blaschek, A, additional, Havla, J, additional, Krumbholz, M, additional, Pöllmann, W, additional, Feneberg, W, additional, Hohlfeld, R, additional, and Lohse, P, additional
- Published
- 2012
- Full Text
- View/download PDF
40. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
- Author
-
Pellkofer, H. L., primary, Krumbholz, M., additional, Berthele, A., additional, Hemmer, B., additional, Gerdes, L. A., additional, Havla, J., additional, Bittner, R., additional, Canis, M., additional, Meinl, E., additional, Hohlfeld, R., additional, and Kuempfel, T., additional
- Published
- 2011
- Full Text
- View/download PDF
41. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group”.
- Author
-
Havla, J, Berthele, A, Kümpfel, T, Krumbholz, M, Jochim, A, Kronsbein, H, Ryschkewitsch, C, Jensen, P, Lippmann, K, Hemmer, B, Major, E, and Hohlfeld, R
- Subjects
- *
DISEASE relapse , *MULTIPLE sclerosis , *NATALIZUMAB , *JOHN Cunningham virus , *PROGRESSIVE multifocal leukoencephalopathy , *GENE amplification , *CEREBROSPINAL fluid - Abstract
We observed two cases of progressive multifocal leukoencephalopathy (PML) that occurred in the same “infusion group”. The group consisted of four patients with relapsing–remitting multiple sclerosis (RRMS) who had been treated with natalizumab (NAT) in the same medical practice for more than four years at the same times and in the same room, raising concerns about viral transmission between members of the infusion group.DNA amplification and sequence comparison of the non-coding control region (NCCR) of JC virus (JCV) present in cerebrospinal fluid (CSF) samples from PML patients #1 and #2 revealed that the amplified JCV sequences differed from the JCV archetype. The NCRR of the viral DNA was unique to each patient, arguing against the possibility of viral transmission between patients. Statistical considerations predict that similar co-occurrences of PML are likely to happen in the future. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
42. THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy
- Author
-
Schoenecker, S., Brendel, M., Havla, J., Hoeglinger, G., Boetzel, K., Danek, A., Rominger, A., and Johannes Levin
43. Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study
- Author
-
Nolan, R., Akhand, O., Calabresi, P., Paul, F., Hernandez Martinez Lapiscina, E., Axel Petzold, Brandt, A., Saidha, S., Villoslada, P., Abu Al-Hassan, A., Behbehani, R., Frohman, E., Frohman, T., Havla, J., Hemmer, B., Jiang, H., Knier, B., Korn, T., Leocani, L., Papadopoulou, A., Pisa, M., Zimmermann, H., Galetta, S., and Balcer, L.
44. Utility of THK-5351 tau-PET for differential diagnosis in patients with hypokinetic-rigid syndromes
- Author
-
Rohrer, G., Schoenecker, S., Brendel, M., Havla, J., Hoeglinger, G., Lindner, S., Zach, C., Vettermann, F., Prix, C., Nuebling, G., Bartenstein, P., Furukawa, K., Ishiki, A., Okamura, N., Boetzel, K., Rominger, A., and Johannes Levin
45. Revising the Advised Protocol for Optical coherence tomography Study Terminology and Elements (APOSTEL): from recommendations to formal guidelines
- Author
-
Cruz-Herranz, A., Aytulun, A., Balk, L., Maier, O., Zimmermann, H., Feltgen, N., Wolf, S., Holz, F., Finger, R., Azuara-Blanco, A., Piero Barboni, Rebolleda, G., Sanchez-Dalmau, B., Debuc, D. Cabrera, Gabilondo, I., Havla, J., Imitola, J., Toosy, A., Outteryck, O., Nolan, R., Kolbe, S., Frederiksen, J. L., Leocani, L., Yeh, A., Ringelstein, M., Pihl-Jensen, G., Preiningerova, J. L., Schippling, S., Costello, F., Aktas, O., Hartung, H-P, Saidha, S., Martinez-Lapiscina, E. H., Lagreze, W. A., Schuman, J. S., Villoslada, P., Calabresi, P., Balcer, L., Petzold, A., Paul, F., Green, A. J., Brandt, A. U., and Albrecht, P.
46. APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies
- Author
-
Jennifer S. Graves, Robert P. Finger, Gema Rebolleda, Aykut Aytulun, Elliot Frohman, Ari J. Green, Peter A. Calabresi, Frank G. Holz, Bernardo Sanchez-Dalmau, Wolf A. Lagrèze, Sven G. Meuth, Lisanne J. Balk, Joachim Havla, Hanna Zimmermann, Laura J. Balcer, Patrick Yu-Wai-Man, Philipp Albrecht, Joel S. Schuman, Alexander U. Brandt, Piero Barboni, P. Villoslada, David Garway-Heath, Sven Schippling, Benjamin Knier, Friedemann Paul, Thomas Korn, Letizia Leocani, Scott Kolbe, Delia Cabrera DeBuc, Teresa Frohman, Jette Lautrup Frederiksen, Andrés Cruz-Herranz, Jaime Imitola, Robert C. Sergott, Oliver Maier, Augusto Azuara Blanco, Hans-Peter Hartung, Orhan Aktas, Julia Krämer, Marius Ringelstein, Elena H. Martinez-Lapiscina, Nicolas Feltgen, Rachel Kenney, Iñigo Gabilondo, Ahmed Toosy, E. Ann Yeh, Sebastian Wolf, Gorm Pihl-Jensen, Olivier Outteryck, Axel Petzold, Fiona Costello, Shiv Saidha, Jana Lizrova Preiningerova, Alexander Klistorner, Neurology, Ophthalmology, APH - Mental Health, APH - Methodology, Amsterdam Neuroscience - Neuroinfection & -inflammation, Aytulun, A., Cruz-Herranz, A., Aktas, O., Balcer, L. J., Balk, L., Barboni, P., Blanco, A. A., Calabresi, P. A., Costello, F., Sanchez-Dalmau, B., Debuc, D. C., Feltgen, N., Finger, R. P., Frederiksen, J. L., Frohman, E., Frohman, T., Garway-Heath, D., Gabilondo, I., Graves, J. S., Green, A. J., Hartung, H. -P., Havla, J., Holz, F. G., Imitola, J., Kenney, R., Klistorner, A., Knier, B., Korn, T., Kolbe, S., Kramer, J., Lagreze, W. A., Leocani, L., Maier, O., Martinez-Lapiscina, E. H., Meuth, S., Outteryck, O., Paul, F., Petzold, A., Pihl-Jensen, G., Preiningerova, J. L., Rebolleda, G., Ringelstein, M., Saidha, S., Schippling, S., Schuman, J. S., Sergott, R. C., Toosy, A., Villoslada, P., Wolf, S., Yeh, E. A., Yu-Wai-Man, P., Zimmermann, H. G., Brandt, A. U., and Albrecht, P.
- Subjects
Research design ,medicine.medical_specialty ,Consensus ,Delphi Technique ,Computer science ,Delphi method ,MEDLINE ,610 Medicine & health ,Terminology ,03 medical and health sciences ,0302 clinical medicine ,Retinal Diseases ,medicine ,Humans ,Medical physics ,030212 general & internal medicine ,Research Methods in Neurology ,Grading (education) ,Protocol (science) ,Guideline ,Checklist ,ddc ,Ophthalmology ,Research Design ,Neurology (clinical) ,Function and Dysfunction of the Nervous System ,030217 neurology & neurosurgery ,Tomography, Optical Coherence - Abstract
ObjectiveTo update the consensus recommendations for reporting of quantitative optical coherence tomography (OCT) study results, thus revising the previously published Advised Protocol for OCT Study Terminology and Elements (APOSTEL) recommendations.MethodsTo identify studies reporting quantitative OCT results, we performed a PubMed search for the terms “quantitative” and “optical coherence tomography” from 2015 to 2017. Corresponding authors of the identified publications were invited to provide feedback on the initial APOSTEL recommendations via online surveys following the principle of a modified Delphi method. The results were evaluated and discussed by a panel of experts and changes to the initial recommendations were proposed. A final survey was recirculated among the corresponding authors to obtain a majority vote on the proposed changes.ResultsA total of 116 authors participated in the surveys, resulting in 15 suggestions, of which 12 were finally accepted and incorporated into an updated 9-point checklist. We harmonized the nomenclature of the outer retinal layers, added the exact area of measurement to the description of volume scans, and suggested reporting device-specific features. We advised to address potential bias in manual segmentation or manual correction of segmentation errors. References to specific reporting guidelines and room light conditions were removed. The participants' consensus with the recommendations increased from 80% for the previous APOSTEL version to greater than 90%.ConclusionsThe modified Delphi method resulted in an expert-led guideline (evidence Class III; Grading of Recommendations, Assessment, Development and Evaluations [GRADE] criteria) concerning study protocol, acquisition device, acquisition settings, scanning protocol, funduscopic imaging, postacquisition data selection, postacquisition analysis, nomenclature and abbreviations, and statistical approach. It will be essential to update these recommendations to new research and practices regularly.
- Published
- 2021
47. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
- Author
-
Havla, Joachim, Pakeerathan, Thivya, Schwake, Carolin, Bennett, Jeffrey L., Kleiter, Ingo, Felipe Rucián, Ana, Institut Català de la Salut, [Havla J] Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany. Data Integration for Future Medicine (DIFUTURE) Consortium, LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany. [Pakeerathan T, Schwake C] Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. [Bennett JL] Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado Anschutz Medical Campus, Denver, USA. [Kleiter I] Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany. [Felipe-Rucián A] Servei de Neurologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
genetic structures ,Retina - Malalties - Imatgeria ,técnicas de investigación::imágenes ópticas::tomografía óptica::tomografía de coherencia óptica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Nervous System Diseases::Neurologic Manifestations::Sensation Disorders::Vision Disorders [DISEASES] ,Other subheadings::Other subheadings::/immunology [Other subheadings] ,Neurologia pediàtrica ,Investigative Techniques::Optical Imaging::Tomography, Optical::Tomography, Optical Coherence [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Otros calificadores::Otros calificadores::/inmunología [Otros calificadores] ,personas::Grupos de Edad::niño [DENOMINACIONES DE GRUPOS] ,Persons::Age Groups::Child [NAMED GROUPS] ,Trastorns de la visió ,enfermedades del sistema nervioso::manifestaciones neurológicas::trastornos sensoriales::trastornos de la visión [ENFERMEDADES] - Abstract
Neuritis òptica; Tomografia de coherència òptica Neuritis óptica; Tomografía de coherencia óptica Optic neuritis; Optical coherence tomography Background To investigate age-related severity, patterns of retinal structural damage, and functional visual recovery in pediatric and adult cohorts of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) optic neuritis (ON). Methods All MOGAD patients from the 5 participating centers were included. Patients with initial manifestation 0.5) visual impairment. Independent of retinal atrophy, age at ON onset significantly correlated with visual outcome. Conclusion Pediatric MOGAD ON showed better visual recovery than adult MOGAD ON despite profound and almost identical neuroaxonal retinal atrophy. Age-related cortical neuroplasticity may account for the substantial discrepancy between structural changes and functional outcomes. JH is (partially) funded by the German Federal Ministry of Education and Research (Grant Numbers 01ZZ1603[A-D] and 01ZZ1804[A-H] (DIFUTURE)). Open Access funding enabled and organized by Projekt DEAL.
- Published
- 2021
48. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study
- Author
-
Elena H. Martinez-Lapiscina, Bernhard Hemmer, Teresa C. Frohman, Pablo Villoslada, Raed Behbehani, Alexander U. Brandt, Abdullah Abu Al-Hassan, Benjamin Knier, Omar Akhand, Hanna Zimmermann, Lisanne J. Balk, Hong Jiang, Letizia Leocani, Shiv Saidha, Athina Papadopoulou, Steven L. Galetta, Rachel Nolan-Kenney, Friedemann Paul, Elliot M. Frohman, Thomas Korn, Axel Petzold, Mengling Liu, Joachim Havla, Marco Pisa, Peter A. Calabresi, Laura J. Balcer, Ophthalmology, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Mental Health, APH - Methodology, Neurology, Nolan-Kenney, R. C., Liu, M., Akhand, O., Calabresi, P. A., Paul, F., Petzold, A., Balk, L., Brandt, A. U., Martinez-Lapiscina, E. H., Saidha, S., Villoslada, P., Al-Hassan, A. A., Behbehani, R., Frohman, E. M., Frohman, T., Havla, J., Hemmer, B., Jiang, H., Knier, B., Korn, T., Leocani, L., Papadopoulou, A., Pisa, M., Zimmermann, H., Galetta, S. L., and Balcer, L. J.
- Subjects
Adult ,Male ,Retinal Ganglion Cells ,0301 basic medicine ,medicine.medical_specialty ,Internationality ,Multiple Sclerosis ,Adolescent ,genetic structures ,Visual Acuity ,Nerve fiber layer ,Retinal Ganglion Cell ,Nerve fiber ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Ophthalmology ,Multiple Sclerosi ,medicine ,Humans ,Optic neuritis ,Retinal thinning ,Aged ,business.industry ,Multiple sclerosis ,Optic Nerve ,Middle Aged ,medicine.disease ,Inner plexiform layer ,eye diseases ,Ganglion ,030104 developmental biology ,medicine.anatomical_structure ,Neurology ,Retinal Neuron ,Optic nerve ,Female ,sense organs ,Neurology (clinical) ,Cohort Studie ,business ,Tomography, Optical Coherence ,030217 neurology & neurosurgery ,Human ,Retinal Neurons - Abstract
Objective To determine the optimal thresholds for intereye differences in retinal nerve fiber and ganglion cell + inner plexiform layer thicknesses for identifying unilateral optic nerve lesions in multiple sclerosis. Current international diagnostic criteria for multiple sclerosis do not include the optic nerve as a lesion site despite frequent involvement. Optical coherence tomography detects retinal thinning associated with optic nerve lesions. Methods In this multicenter international study at 11 sites, optical coherence tomography was measured for patients and healthy controls as part of the International Multiple Sclerosis Visual System Consortium. High- and low-contrast acuity were also collected in a subset of participants. Presence of an optic nerve lesion for this study was defined as history of acute unilateral optic neuritis. Results Among patients (n = 1,530), receiver operating characteristic curve analysis demonstrated an optimal peripapillary retinal nerve fiber layer intereye difference threshold of 5μm and ganglion cell + inner plexiform layer threshold of 4μm for identifying unilateral optic neuritis (n = 477). Greater intereye differences in acuities were associated with greater intereye retinal layer thickness differences (p ≤ 0.001). Interpretation Intereye differences of 5μm for retinal nerve fiber layer and 4μm for macular ganglion cell + inner plexiform layer are robust thresholds for identifying unilateral optic nerve lesions. These thresholds may be useful in establishing the presence of asymptomatic and symptomatic optic nerve lesions in multiple sclerosis and could be useful in a new version of the diagnostic criteria. Our findings lend further validation for utilizing the visual system in a multiple sclerosis clinical trial setting. Ann Neurol 2019;85:618-629.
- Published
- 2019
49. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
- Author
-
Maria Isabel Leite, Letizia Leocani, Jérôme De Seze, Denis Bernardi Bichuetti, Ibis Soto de Castillo, Sasitorn Siritho, Alvaro Cobo-Calvo, Elena H. Martinez-Lapiscina, Anitha D'Cunha, Adriana Roca-Fernandez, Jacqueline Palace, Orhan Aktas, Marco Aurélio Lana-Peixoto, Marco Pisa, Michael R. Yeaman, Anu Jacob, Mariana Andrade Fontenelle, Friedemann Paul, Ari J. Green, Yang Mao-Draayer, Eugene F May, Claudia Chien, Alireza Dehghani, Ivan Maynart Tavares, Lawrence J. Cook, Angelo Lu, Su-Kyung Jung, Rengin Yildirim, Ayse Altintas, Mohsen Pourazizi, Ho Jin Kim, Rahele Kafieh, Caryl Tongco, Lekha Pandit, Hadas Stiebel-Kalish, Romain Marignier, Fereshteh Ashtari, Hanna Zimmermann, Joachim Havla, M. Radaelli, Svenja Specovius, Frederike C. Oertel, Kerstin Soelberg, Srilakshmi M Sharma, Axel Petzold, Seyedamirhosein Motamedi, Zoe Rimler, Saif Huda, Philipp Albrecht, Alexander U. Brandt, Jae-Won Hyun, Allyson Reid, Marius Ringelstein, Uygur Tanriverdi, Terry J. Smith, Thomas Senger, Nasrin Asgari, Charlotte Bereuter, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Lu, A., Zimmermann, HG., Specovius, S., Motamedi, S., Chien, C., Bereuter, C., Lana-Peixoto, MA., Fontenelle, MA., Ashtari, F., Kafieh, R., Dehghani, A., Pourazizi, M., Pandit, L., D Cunha, A., Kim, HJ., Hyun, JW., Jung, SK., Leocani, L., Pisa, M., Radaelli, M., Siritho, S., May, E.F., Tongco, C., De Sèze, J., Senger, T., Palace, J., Roca-Fernández, A., Leite, MI., Sharma, SM., Stiebel-Kalish, H., Asgari, N., Soelberg, K.K., Martinez-Lapiscina, EH., Havla, J., Mao-Draayer, Y., Rimler, Z., Reid, A., Marignier, R., Cobo-Calvo, A., Tanriverdi, U., Yildirim, R., Aktas, O., Ringelstein, M., Albrecht, P., Tavares, IM., Bichuetti, DB., Jacob, A., Huda, S., Soto de Castillo, I., Petzold, A., Green, AJ., Yeaman, MR., Smith, TJ., Cook, L., Paul, F., Brandt, AU., Oertel, FC., GJCF International Clinical Consortium for NMOSD., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Neurology, Ophthalmology, APH - Mental Health, APH - Methodology, and Amsterdam Neuroscience - Neuroinfection & -inflammation
- Subjects
Adult ,Male ,medicine.medical_specialty ,genetic structures ,Vision ,Clinical neurology ,Ophthalmology ,Outer plexiform layer ,Retina ,chemistry.chemical_compound ,medicine ,Humans ,In patient ,Optic neuritis ,Outer nuclear layer ,Autoantibodies ,Aquaporin 4 ,business.industry ,Neuromyelitis Optica ,Retinal ,Middle Aged ,medicine.disease ,eye diseases ,Neurosciences and neurology ,Psychiatry ,Surgery ,Psychiatry and Mental health ,medicine.anatomical_structure ,Retinal dysfunction ,Cross-Sectional Studies ,chemistry ,Neuromyelitis Optica Spectrum Disorders ,Astrocytes ,Female ,Neurology (clinical) ,sense organs ,business ,Function and Dysfunction of the Nervous System ,Axonal degeneration ,Tomography, Optical Coherence - Abstract
Background: patients with anti-aquaporin-4 antibody seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorders (NMOSDs) frequently suffer from optic neuritis (ON) leading to severe retinal neuroaxonal damage. Further, the relationship of this retinal damage to a primary astrocytopathy in NMOSD is uncertain. Primary astrocytopathy has been suggested to cause ON-independent retinal damage and contribute to changes particularly in the outer plexiform layer (OPL) and outer nuclear layer (ONL), as reported in some earlier studies. However, these were limited in their sample size and contradictory as to the localisation. This study assesses outer retinal layer changes using optical coherence tomography (OCT) in a multicentre cross-sectional cohort. Method: 197 patients who were AQP4-IgG+ and 32 myelin-oligodendrocyte-glycoprotein antibody seropositive (MOG-IgG+) patients were enrolled in this study along with 75 healthy controls. Participants underwent neurological examination and OCT with central postprocessing conducted at a single site. Results: no significant thinning of OPL (25.02 +/- 2.03 mu m) or ONL (61.63 +/- 7.04 mu m) were observed in patients who were AQP4-IgG+ compared with patients who were MOG-IgG+ with comparable neuroaxonal damage (OPL: 25.10 +/- 2.00 mu m; ONL: 64.71 +/- 7.87 mu m) or healthy controls (OPL: 24.58 +/- 1.64 mu m; ONL: 63.59 +/- 5.78 mu m). Eyes of patients who were AQP4-IgG+ (19.84 +/- 5.09 mu m, p=0.027) and MOG-IgG+ (19.82 +/- 4.78 mu m, p=0.004) with a history of ON showed parafoveal OPL thinning compared with healthy controls (20.99 +/- 5.14 mu m); this was not observed elsewhere. Conclusion: the results suggest that outer retinal layer loss is not a consistent component of retinal astrocytic damage in AQP4-IgG+ NMOSD. Longitudinal studies are necessary to determine if OPL and ONL are damaged in late disease due to retrograde trans-synaptic axonal degeneration and whether outer retinal dysfunction occurs despite any measurable structural correlates., Guthy Jackson Charitable Foundation (GJCF); German Research Foundation (DFG)
- Published
- 2021
50. Prognostic models in multiple sclerosis: progress and challenges in clinical integration.
- Author
-
Havla J, Reeve K, On BI, Mansmann U, and Held U
- Abstract
As a chronic inflammatory disease of the central nervous system, multiple sclerosis (MS) is of great individual health and socio-economic significance. To date, there is no prognostic model that is used in routine clinical care to predict the very heterogeneous course of the disease. Despite several research groups working on different prognostic models using traditional statistics, machine learning and/or artificial intelligence approaches, the use of published models in clinical decision making is limited because of poor model performance, lack of transferability and/or lack of validated models. To provide a systematic overview, we conducted a "Cochrane review" that assessed 75 published prediction models using relevant checklists (CHARMS, PROBAST, TRIPOD). We have summarized the relevant points from this analysis here so that the use of prognostic models for therapy decisions in clinical routine can be successful in the future., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.